Janux Therapeutics IncNASDAQ:JANX
- LAST PRICE45.2100
- TODAY'S CHANGE (%)-1.1800 (-2.5437%)
- Bid / Lots45.0000/ 1
- Ask / Lots45.5000/ 2
- Open / Previous Close46.1300 / 46.3900
- Day Range
- 52 Week Range
- Volume534,619
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | JANX |
|---|---|---|
| 09:32 ET | 2317 | 46.72 |
| 09:33 ET | 900 | 46.72 |
| 09:35 ET | 700 | 46.57 |
| 09:39 ET | 144 | 46.5 |
| 09:42 ET | 100 | 46.21 |
| 09:44 ET | 100 | 46.34 |
| 09:46 ET | 1056 | 46.35 |
| 09:48 ET | 700 | 46.35 |
| 09:50 ET | 3600 | 46.42 |
| 09:51 ET | 3700 | 46.4 |
| 09:53 ET | 100 | 46.4 |
| 09:55 ET | 200 | 46.415 |
| 09:57 ET | 300 | 46.425 |
| 10:00 ET | 622 | 46.365 |
| 10:02 ET | 4815 | 46.19 |
| 10:04 ET | 500 | 46.195 |
| 10:06 ET | 1100 | 46.225 |
| 10:08 ET | 200 | 46.19 |
| 10:09 ET | 509 | 46.2 |
| 10:11 ET | 1214 | 46.205 |
| 10:13 ET | 17222 | 46.625 |
| 10:15 ET | 12916 | 46.385 |
| 10:18 ET | 2090 | 46.195 |
| 10:20 ET | 521 | 46.03 |
| 10:22 ET | 100 | 46.195 |
| 10:24 ET | 300 | 46.215 |
| 10:26 ET | 100 | 46.19 |
| 10:27 ET | 5986 | 46.035 |
| 10:29 ET | 1400 | 46.07 |
| 10:31 ET | 600 | 46.13 |
| 10:33 ET | 1944 | 46.165 |
| 10:36 ET | 100 | 46.27 |
| 10:38 ET | 100 | 46.21 |
| 10:40 ET | 6000 | 46.2568 |
| 10:42 ET | 1000 | 46.185 |
| 10:44 ET | 300 | 46.175 |
| 10:45 ET | 3543 | 46.07 |
| 10:47 ET | 767 | 46.14 |
| 10:49 ET | 203 | 46.15 |
| 10:51 ET | 911 | 46.35 |
| 10:54 ET | 200 | 46.36 |
| 10:56 ET | 400 | 46.205 |
| 10:58 ET | 2275 | 46.43 |
| 11:00 ET | 300 | 46.26 |
| 11:02 ET | 2027 | 46.275 |
| 11:03 ET | 350 | 46.28 |
| 11:05 ET | 966 | 46.14 |
| 11:07 ET | 12296 | 45.94 |
| 11:09 ET | 1463 | 45.93 |
| 11:12 ET | 100 | 45.93 |
| 11:14 ET | 300 | 45.935 |
| 11:16 ET | 2846 | 45.92 |
| 11:18 ET | 900 | 45.81 |
| 11:20 ET | 300 | 45.815 |
| 11:21 ET | 400 | 45.805 |
| 11:23 ET | 200 | 45.81 |
| 11:25 ET | 1800 | 45.93 |
| 11:27 ET | 400 | 46.12 |
| 11:30 ET | 700 | 46.02 |
| 11:32 ET | 700 | 45.96 |
| 11:34 ET | 1752 | 46 |
| 11:36 ET | 400 | 46.055 |
| 11:38 ET | 2210 | 46 |
| 11:39 ET | 400 | 46.035 |
| 11:41 ET | 2096 | 46 |
| 11:43 ET | 900 | 45.98 |
| 11:45 ET | 700 | 46.005 |
| 11:48 ET | 7894 | 45.83 |
| 11:50 ET | 975 | 45.8 |
| 11:52 ET | 3566 | 45.71 |
| 11:54 ET | 4120 | 45.575 |
| 11:56 ET | 1800 | 45.56 |
| 11:57 ET | 300 | 45.48 |
| 11:59 ET | 1205 | 45.47 |
| 12:01 ET | 200 | 45.54 |
| 12:03 ET | 7196 | 45.51 |
| 12:06 ET | 4050 | 45.78 |
| 12:08 ET | 200 | 45.785 |
| 12:10 ET | 800 | 45.69 |
| 12:12 ET | 3140 | 45.65 |
| 12:14 ET | 1040 | 45.62 |
| 12:15 ET | 200 | 45.51 |
| 12:17 ET | 520 | 45.42 |
| 12:19 ET | 2820 | 45.575 |
| 12:21 ET | 200 | 45.575 |
| 12:24 ET | 549 | 45.51 |
| 12:26 ET | 1002 | 45.575 |
| 12:28 ET | 4674 | 45.65 |
| 12:30 ET | 12664 | 46 |
| 12:32 ET | 5068 | 46 |
| 12:33 ET | 8078 | 45.87 |
| 12:35 ET | 3405 | 45.9 |
| 12:37 ET | 3421 | 45.81 |
| 12:39 ET | 14657 | 45.455 |
| 12:42 ET | 2626 | 45.58 |
| 12:44 ET | 5452 | 45.58 |
| 12:46 ET | 5550 | 45.55 |
| 12:48 ET | 11765 | 45.4 |
| 12:50 ET | 3730 | 45.43 |
| 12:51 ET | 8921 | 45.39 |
| 12:53 ET | 5311 | 45.445 |
| 12:55 ET | 5986 | 45.54 |
| 12:57 ET | 10264 | 45.58 |
| 01:00 ET | 82269 | 45.21 |
Nov 25, 2024
Nov 22, 2024
DJ Janux Therapeutics Initiated at Outperform by Leerink Partners, from 8:20AM ET on Friday Nov 22, 2024 by Dow Jones
8:20AM ET on Friday Nov 22, 2024 by Dow Jones
Nov 15, 2024
DJ 13D Filings -- Barron's, from 9:30PM ET on Friday Nov 15, 2024 by Dow Jones
9:30PM ET on Friday Nov 15, 2024 by Dow JonesDJ Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors -- Barrons.com, from 8:34PM ET on Friday Nov 15, 2024 by Dow Jones
8:34PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 7, 2024
DJ Janux Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co., from 3:37PM ET on Thursday Nov 07, 2024 by Dow Jones
3:37PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Janux Therapeutics Inc | 2.4B | -38.5x | --- |
Geron Corp | 2.5B | -12.8x | --- |
Soleno Therapeutics Inc | 2.4B | -15.9x | --- |
Keros Therapeutics Inc | 2.4B | -11.1x | --- |
Longboard Pharmaceuticals Inc | 2.3B | -26.8x | --- |
Centessa Pharmaceuticals PLC | 2.3B | -11.7x | --- |
Company Information
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Contact Information
- Headquarters
- 10955 Vista Sorrento Parkway, Suite 200SAN DIEGO, CA, United States 92130
- Phone
- 858-751-4493
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Ronald Barrett
- President, Chief Executive Officer, Founder, Director
- David Campbell
- Co-Founder, Chief Scientific Officer
- Tommy Diraimondo
- Acting Chief Financial Officer
- Tighe Reardon
- Chief Technology Officer
- Charles Winter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
|---|---|
Revenue (TTM) | $13.0M |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.33 |
EPS | $-1.18 |
Book Value | $7.44 |
P/E Ratio | -38.5x |
Price/Sales (TTM) | 186.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -658.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
